title: The "glucose pentagon": assessing glycemic control of patients with diabetes mellitus by a model integrating different parameters from glucose profiles.
abstract: Measuring the hemoglobin A(1c) (HbA(1c)) is the standard-of-care method to assess long-term glycemic control of patients with diabetes, describing the average glycemic level. However, the HbA(1c) does not reflect acute fluctuations in glucose levels. Variability of glycemia probably has an impact on the development of diabetes-related late complications. A novel model presented in this article combines different summary measures derived from continuously recorded glucose profiles (including parameters describing glycemic variability) and the HbA(1c). The five parameters taking into account are the axes of a "glucose pentagon." Connecting the values of these parameters provided an enclosed area of a given size. For a patient with diabetes, these parameters and the connected area describe how his or her glycemia was during the monitoring period. The area of the glucose pentagon for a patient with diabetes, divided by the standard area of healthy subjects, yields a non-dimensional characteristic value defined as the glycemic risk parameter. It is assume that this risk parameter provides a more meaningful overall description of metabolic control than the HbA(1c) alone. In addition, it might also allow a better assessment of a patient's risk for developing diabetes-related late complications in comparison to the HbA(1c) alone. Of critical importance is, of course, that the clinical relevance of the glucose pentagon is verified in adequate long-term clinical studies.
authors.affiliation: Medtronic GmbH, Meerbusch, Germany. andrea.thomas@medtronic.com
authors.forename: Andreas
authors.initials: A
authors.lastname: Thomas
authors.forename: Martin
authors.initials: M
authors.lastname: Schönauer
authors.forename: Frank
authors.initials: F
authors.lastname: Achermann
authors.forename: Oliver
authors.initials: O
authors.lastname: Schnell
authors.forename: Markolf
authors.initials: M
authors.lastname: Hanefeld
authors.forename: Hans-Jürgen
authors.initials: HJ
authors.lastname: Ziegelasch
authors.forename: John
authors.initials: J
authors.lastname: Mastrototaro
authors.forename: Lutz
authors.initials: L
authors.lastname: Heinemann
mesh_terms: D019540:Area Under Curve; D001786:Blood Glucose / Q000378:metabolism*; D003920:Diabetes Mellitus / Q000097:blood* / Q000188:drug therapy; D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000188:drug therapy; D006442:Glycated Hemoglobin / Q000378:metabolism*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007328:Insulin / Q000627:therapeutic use; D008962:Models, Theoretical; D018670:Monitoring, Ambulatory; D015588:Observer Variation
chemical_list: D001786:Blood Glucose; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D007328:Insulin